Bharat Biotech finds Covaxin 81% efficient in Phase 3 trials

Bharat Biotech's vaccine, whose emergency use approval before finishing final stage testing had triggered a row, has shown an 81 per cent efficacy in preventing symptomatic COVID-19 in an interim......

Zydus PAT rises 38% on strong India, US growth

Ahmedabad-headquartered Zydus Lifesciences posted a 17 per cent year-on-year (Y-o-Y) rise in revenue from operations to Rs 6,123 crore, while the net profit increased by 38 per cent to Rs 1,258.6......